|
|
ChanTest discovery services – early screens save you time & resources
Too often, drug-development researchers identify unacceptable safety risks late in the drug-development process – during the GLP patch-clamp studies that are required for IND submission. When completed early in the drug-discovery process, ChanTest’s functional ion channel screens can save considerable time, money, and other resources.
ChanTest sets the standard for selectivity and safety profiling of drug candidates. Unlike most service organizations, ChanTest has validated its cell lines for testing at each phase of the drug-discovery process. Whether you need initial high-throughput screening of hits, high-sensitivity screens for lead identification and lead optimization, or safety testing in preparation for an IND submission – your ChanTest results will correlate. Fast, accurate, reliable screens for profiling off-target effects At ChanTest, we stand by our results. Our profiling screens are:
ChanTest offers the broadest selection of predictive ion channel assays
ChanTest has built the largest ion channel library in the world to meet the drug discovery needs of our customers. Library “books” form the Cardiac Channel Panel™ to complement the FDA and ICH S7B cardiac safety guidance. Library books also form CNS, CVS, and Respiratory Channel Panels™ to complement the FDA and ICH S7A safety guidance. Our Channel Panels are FDA Critical Path tools for efficiently moving drug candidates through development. And our Ion Channel CatalogTM of validated ion channel-expressing cell lines is growing.
Click here for the latest list, or here for descriptions of our discovery assays, or to download information sheets. Click here to complete and e-mail an interactive applications form to ChanTest scientists, or call 216.332.1665 for more information.
|
|
|
|